Department of Neurology, Medical University of Warsaw, Warsaw, Poland.
Poznan University of Medical Sciences, Department of Neurology, Division of Neurochemistry and Neuropathology, Poznan, Poland.
Neurol Neurochir Pol. 2021;55(1):8-11. doi: 10.5603/PJNNS.a2021.0016. Epub 2021 Feb 8.
A working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society has developed a statement with regard to the currently available mRNA vaccines (Pfizer-BioNTech and Moderna) preventing novel coronavirus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) infection, which causes Coronavirus disease 2019 (COVID-19), in patients with multiple sclerosis (MS). This statement has been based on the literature available as of 15 January, 2021. The guidance will be updated as new data emerges. All data regarding the above-mentioned vaccines comes from clinical trials which have been reviewed, published and approved by the regulatory authorities [1, 2]. In the current manuscript, whenever a SARS-CoV-2 vaccine is discussed, it refers to mRNA vaccines only.
波兰神经病学会多发性硬化症和神经免疫学分会召集的一个工作组就目前可用的 mRNA 疫苗（辉瑞-生物技术公司和 Moderna）在预防新型冠状病毒（严重急性呼吸系统综合征冠状病毒 2，SARS-CoV-2）感染方面发表了一份声明，新型冠状病毒感染导致 2019 年冠状病毒病（COVID-19）。该声明是基于截至 2021 年 1 月 15 日的文献资料。随着新数据的出现，指南将不断更新。所有关于上述疫苗的数据均来自已被监管机构审查、发布和批准的临床试验[1,2]。在本文稿中，每当讨论 SARS-CoV-2 疫苗时，仅指 mRNA 疫苗。
